New Gut-Targeting drug takes first step in human trials
NCT ID NCT06835296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new oral drug called YUQ-A1007 in 47 healthy adults aged 18 to 65. The drug is designed to activate a protein in the gut that may help treat inflammatory bowel disease (IBD). The main goal was to check the drug's safety, tolerability, and how the body processes it. Since this is the first time the drug has been given to humans, no conclusions about its effectiveness for IBD can be drawn yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YUQ-A1007 (an oral drug that activates a protein called AhR in the gut)
What this could lead to
If safe and well-tolerated, this could pave the way for future studies testing YUQ-A1007 as a treatment for inflammatory bowel disease (IBD).
What could go wrong
This is a very early, first-in-human study in only 47 healthy people. It is designed only to check safety, not to see if the drug works for any disease. Many early-stage drugs fail to show benefit in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain Metabolism Study Using PET/fMRI (NCT05756335)
- Short-term arm immobilization & muscle metabolis NCT06750497
- Parent-led app boosts kids' motor & brain skills NCT07680075
- DigiKids App-Based Motor Skills Trial for Kids (NCT07679633)
- QX-4533 Safety Study in Healthy People | NCT07678463
- Pomegranate Supplement & Gut Health in Alcohol L NCT07678567
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States